To determine the extent of subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis (RR MS) receiving disease-modifying drugs (DMD).
No takes yet. Share an insight, caveat, or question.
Omerzu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: